Archive \ Volume.16 2025 Issue 4

Digital Pharmacy Services and Unequal Access to Medicines: An Integrative Review of Equity Consequences

, ,
  1. Department of Pharmacy Equity and Digital Access, School of Pharmacy, Trinity College Dublin, Dublin, Ireland.
  2. Department of Health Equity and Digital Pharmacy, School of Pharmacy, University College Cork, Cork, Ireland.

Abstract

Digital pharmacy services increasingly mediate how patients obtain medicines, advice, and follow-up. Their expansion may reduce distance and time barriers, but benefits are not distributed uniformly because connectivity, affordability, literacy, language, disability, trust, and organizational capacity shape use. To integrate empirical, theoretical, and policy-relevant evidence on how digital pharmacy services influence unequal access to medicines, who benefits, who encounters barriers, and which contextual conditions reduce or amplify inequity. A transparent integrative review used a protocol-defined search, eligibility criteria, record-level screening, source-type-sensitive appraisal, structured extraction, comparative data reduction, and thematic synthesis. Access was treated as multidimensional rather than equivalent to service availability. Evidence was compared across digital access, affordability, reach, literacy, language, disability, usability, geography, organizational capacity, data representation, and algorithmic processes.

Digital pharmacy can extend service reach, support continuity, and reduce travel or scheduling burdens when infrastructure, accessible design, human assistance, and implementation capacity are adequate. The same services can intensify exclusion when participation requires reliable connectivity, suitable devices, digital or health literacy, dominant-language fluency, accessible interfaces, trust, or institutional support. Evidence concerning algorithmic equity remained less mature than evidence concerning telepharmacy and digital access barriers. Reported benefits were therefore conditional, context-dependent, and not interchangeable with equitable access. Digital pharmacy is neither inherently equity-promoting nor inherently exclusionary. Equity consequences arise from interactions among service design, patient resources, organizational arrangements, and data practices. Evaluation should examine who can enter, use, understand, trust, and meaningfully benefit from the service, while retaining nondigital alternatives and escalation routes.


Downloads: 34
Views: 80

How to cite:
Vancouver
O'Leary J, Dunne A, O'Brien S. Digital Pharmacy Services and Unequal Access to Medicines: An Integrative Review of Equity Consequences. Arch Pharm Pract. 2025;16(4):73-81. https://doi.org/10.51847/SgQOuL1Mc5
APA
O'Leary, J., Dunne, A., & O'Brien, S. (2025). Digital Pharmacy Services and Unequal Access to Medicines: An Integrative Review of Equity Consequences. Archives of Pharmacy Practice, 16(4), 73-81. https://doi.org/10.51847/SgQOuL1Mc5

Download Citation
References
  1. Crawford A, Serhal E. Digital health equity and COVID-19: The innovation curve cannot reinforce the social gradient of health. J Med Internet Res. 2020;22(6). doi:10.2196/19361
  2. Sieck CJ, Sheon A, Ancker JS, Castek J, Callahan B, Siefer A. Digital inclusion as a social determinant of health. NPJ Digit Med. 2021;4(1):52. doi:10.1038/s41746-021-00413-8
  3. Richardson S, Lawrence K, Schoenthaler AM, Mann D. A framework for digital health equity. NPJ Digit Med. 2022;5(1):119. doi:10.1038/s41746-022-00663-0
  4. Alexander E, Butler CD, Darr A, Jenkins MT, Long RD, Shipman CJ, et al. ASHP statement on telepharmacy. Am J Health Syst Pharm. 2017;74(9). doi:10.2146/ajhp170039
  5. Snyder H. Literature review as a research methodology: An overview and guidelines. J Bus Res. 2019;104:333-9. doi:10.1016/j.jbusres.2019.07.039
  6. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. doi:10.1136/bmj.n71
  7. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372. doi:10.1136/bmj.n160
  8. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. BMJ. 2020;368. doi:10.1136/bmj.l6890
  9. van Deursen AJAM. Digital inequality during a pandemic: Quantitative study of differences in COVID-19-related internet uses and outcomes among the general population. J Med Internet Res. 2020;22(8). doi:10.2196/20073
  10. Ramsetty A, Adams C. Impact of the digital divide in the age of COVID-19. J Am Med Inform Assoc. 2020;27(7):1147-8. doi:10.1093/jamia/ocaa078
  11. Azzopardi-Muscat N, Sørensen K. Towards an equitable digital public health era: Promoting equity through a health literacy perspective. Eur J Public Health. 2019;29(Suppl 3):13-7. doi:10.1093/eurpub/ckz166
  12. Guadamuz JS, Wilder JR, Mouslim MC, Zenk SN, Alexander GC, Qato DM. Fewer pharmacies in Black and Hispanic/Latino neighborhoods compared with White or diverse neighborhoods, 2007-15. Health Aff (Millwood). 2021;40(5):802-11. doi:10.1377/hlthaff.2020.01699
  13. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ, et al. PRISMA-S: An extension to the PRISMA statement for reporting literature searches in systematic reviews. Syst Rev. 2021;10(1):39. doi:10.1186/s13643-020-01542-z
  14. Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: A prospective exploratory study. Syst Rev. 2017;6(1):245. doi:10.1186/s13643-017-0644-y
  15. Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qual Res Psychol. 2021;18(3):328-52. doi:10.1080/14780887.2020.1769238
  16. Snoswell CL, De Guzman K, Neil LJ, Isaacs T, Mendis R, Taylor ML, et al. Synchronous telepharmacy models of care for adult outpatients: A systematic review. Res Social Adm Pharm. 2025;21(1):1-21. doi:10.1016/j.sapharm.2024.10.005
  17. Dat TV, Tu VL, Quan NK, Minh NH, Trung TD, Le TN, et al. Telepharmacy: A systematic review of field application, benefits, limitations, and applicability during the COVID-19 pandemic. Telemed J E Health. 2023;29(2):209-21. doi:10.1089/tmj.2021.0575
  18. Aboelzahab YH, McCracken A, Abdoulrezzak R, Naguib S, McLean M, Tricco AC, et al. Virtual care in community pharmacy services: A scoping review. Res Social Adm Pharm. 2025;21(9):653-66. doi:10.1016/j.sapharm.2025.03.066
  19. Niznik JD, He H, Kane-Gill SL. Impact of clinical pharmacist services delivered via telemedicine in the outpatient or ambulatory care setting: A systematic review. Res Social Adm Pharm. 2018;14(8):707-17. doi:10.1016/j.sapharm.2017.10.011
  20. Urick BY, Adams JK, Bruce MR. State telepharmacy policies and pharmacy deserts. JAMA Netw Open. 2023;6(8). doi:10.1001/jamanetworkopen.2023.28810
  21. Qato DM, Zenk S, Wilder J, Harrington R, Gaskin D, Alexander GC. The availability of pharmacies in the United States: 2007-2015. PLoS One. 2017;12(8). doi:10.1371/journal.pone.0183172
  22. Jairoun AA, Al-Hemyari SS, Shahwan M, Godman B, El-Dahiyat F, Kurdi A, et al. Access to community pharmacy services for people with disabilities: Barriers, challenges, and opportunities. Res Social Adm Pharm. 2022;18(5):2711-3. doi:10.1016/j.sapharm.2022.01.009
  23. Alfian SD, Sania JA, Aini DQ, Khoiry QA, Griselda M, Ausi Y, et al. Evaluation of usability and user feedback to guide telepharmacy application development in Indonesia: A mixed-methods study. BMC Med Inform Decis Mak. 2024;24(1):130. doi:10.1186/s12911-024-02494-3
  24. Durmuş A. The influence of digital literacy on mHealth app usability: The mediating role of patient expertise. Digit Health. 2024;10:20552076241299061. doi:10.1177/20552076241299061
  25. Nazer LH, Zatarah R, Waldrip S, Ke JXC, Moukheiber M, Khanna AK, et al. Bias in artificial intelligence algorithms and recommendations for mitigation. PLOS Digit Health. 2023;2(6). doi:10.1371/journal.pdig.0000278
  26. Obermeyer Z, Powers B, Vogeli C, Mullainathan S. Dissecting racial bias in an algorithm used to manage the health of populations. Science. 2019;366(6464):447-53. doi:10.1126/science.aax2342
  27. Chen IY, Pierson E, Rose S, Joshi S, Ferryman K, Ghassemi M. Ethical machine learning in healthcare. Annu Rev Biomed Data Sci. 2021;4:123-44. doi:10.1146/annurev-biodatasci-092820-114757
  28. Eberly LA, Kallan MJ, Julien HM, Haynes N, Khatana SAM, Nathan AS, et al. Patient characteristics associated with telemedicine access for primary and specialty ambulatory care during the COVID-19 pandemic. JAMA Netw Open. 2020;3(12). doi:10.1001/jamanetworkopen.2020.31640
  29. Khoong EC, Butler BA, Mesina O, Su G, DeFries TB, Nijagal M, et al. Patient interest in and barriers to telemedicine video visits in a multilingual urban safety-net system. J Am Med Inform Assoc. 2021;28(2):349-53. doi:10.1093/jamia/ocaa234
  30. Veinot TC, Mitchell H, Ancker JS. Good intentions are not enough: How informatics interventions can worsen inequality. J Am Med Inform Assoc. 2018;25(8):1080-8. doi:10.1093/jamia/ocy052
  31. Brewer LC, Fortuna KL, Jones C, Walker R, Hayes SN, Patten CA, et al. Back to the future: Achieving health equity through health informatics and digital health. JMIR Mhealth Uhealth. 2020;8(1). doi:10.2196/14512
  32. Lyles CR, Wachter RM, Sarkar U. Focusing on digital health equity. JAMA. 2021;326(18):1795-6. doi:10.1001/jama.2021.18459
  33. Rodriguez JA, Clark CR, Bates DW. Digital health equity as a necessity in the 21st Century Cures Act era. JAMA. 2020;323(23):2381-2. doi:10.1001/jama.2020.7858
  34. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: A roadmap for responsible machine learning for health care. Nat Med. 2019;25(9):1337-40. doi:10.1038/s41591-019-0548-6
  35. Ong JCL, Seng BJJ, Law JZF, Low LL, Kwa ALH, Giacomini KM, et al. Artificial intelligence, ChatGPT, and other large language models for social determinants of health: Current state and future directions. Cell Rep Med. 2024;5(1):101356. doi:10.1016/j.xcrm.2023.101356
  36. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. Lancet Digit Health. 2021;3(11). doi:10.1016/S2589-7500(21)00208-

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.